BiotechTube
Biodol

Biodol

Paris, France· Est.
biodol.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biodol Therapeutics is a preclinical-stage biotech pioneering a novel approach to chronic neuropathic pain by targeting the FLT3 receptor, a key player in pain pathophysiology. Its proprietary compounds not only reverse pain symptoms in models but also potentiate morphine and abolish opioid-induced tolerance, positioning them to address the opioid crisis. With a strong IP portfolio covering FLT3 inhibition for pain and a recent licensing deal with Kyorin Pharmaceutical, Biodol is advancing lead compounds toward clinical development in a multi-billion dollar market.

Chronic PainNeuropathic Pain

Technology Platform

Development of small-molecule extracellular inhibitors (Negative Allosteric Modulators) of the FLT3 receptor for the treatment of chronic neuropathic pain and for opioid potentiation/tolerance prevention.

Opportunities

The $23B+ chronic pain market, especially in the US, offers a massive opportunity for a novel, non-opioid mechanism.
The opioid-sparing effect of BDT compounds addresses a critical public health crisis, creating a powerful incentive for adoption and premium pricing.
The recent license agreement with Kyorin provides validation, funding, and a path to the Asian market.

Risk Factors

The novel FLT3 mechanism is unproven in humans, carrying clinical development risk.
The broader market strategy is partially dependent on combination use with opioids, a class facing intense regulatory and prescribing scrutiny.
As a small, private company, Biodol remains reliant on partnership and investment capital to fund expensive late-stage development.

Competitive Landscape

There are no known direct competitors developing FLT3 inhibitors for pain. However, the neuropathic pain space is competitive with companies targeting mechanisms like NGF, NaV channels, and various GPCRs. Biodol's key competitive advantage is its first-in-class target, strong IP position, and unique dual mechanism addressing both pain and opioid-related adverse effects.

More companies in Small Molecule Drugs →More companies in France →